The prevalent cases of NMO vary worldwide, In the USA the estimated prevalence is to be approximately 2% to 2.5% that of MS, NMO accounts for a small proportion of demyelinating disease in Caucasians (1–2%), but a much larger percentage in Asians (20–48%). Women are preferentially affected with a female: male ratio of nearly 10:1
Comprehensive insight on patient segmentation based on age, sex, Diagnosis (NMO-IgG Seropositive, NMO-IgG Seropositive), Clinical Characterization based on Acute & Refractory; Transverse Myelitis (Overall, Longitudinally extensive, Focal), Optic Neuritis (Overall, Unilateral, Bilateral), Event types (Transverse Myelitis, Optic Neuritis; Monophasic & Recurrent, has been provided into the epidemiology section of the Neuromyelitis Optica (NMO) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are several drug candidates are in different Phase (II and I/II/ III) stages of development. Key companies are Horizon Pharma, Alexion Pharma, Roche, Viro-Pharma, TG Therapeutics, Bio-Thera, Novartis. Among these key assets, some of the assets is being designated as an orphan drug from EMA and US FDA. The launch of key assets will positively impact the overall market from 2023 to 2030 in 8 MM countries. In March 2016, The U.S. Food and Drug Administration (FDA) granted the drug orphan drug designation for the treatment of NMO and NMOSD. In March 2017, the EMA granted Orphan designation to inebilizumab (formerly MEDI-551) for the treatment of Neuromyelitis Optica spectrum disorder (NMOSD).
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,